The registration procedures have been completed and Marketing Authorizations are to be issued for three new products

By the end of 2018, Tchaikapharma expects to be issued with Marketing Authorizations for three new prescription drugs, which will enrich the portfolio and the well-developed therapeutic baskets of the company with the following medications and indications:

 

Chlorthidon (chlorthalidone) – for the treatment of arterial hypertension, essential or renovascular, or isolated systolic hypertension.

 

PlaquEx Combi (clopidogrel/acetylsalicylic acid) – for the secondary prevention of acute cardiovascular events.

 

Methylprednisolone-Tchaikapharma (methylprednisolone) – for the treatment of endocrine, rheumatic, collagenosis and immune-complex, skin, eye, gastrointestinal, respiratory,  hematological, oncology and edema diseases, as well as allergic conditions.

 

Tchaikapharma International Press Center